Marina Sironi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3995981/publications.pdf Version: 2024-02-01



MADINA SIDONI

#	Article	IF	CITATIONS
1	Differential expression and regulation of MS4A family members in myeloid cells in physiological and pathological conditions. Journal of Leukocyte Biology, 2022, 111, 817-836.	3.3	23
2	Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nature Immunology, 2021, 22, 19-24.	14.5	101
3	Long pentraxin PTX3 is upregulated systemically and centrally after experimental neurotrauma, but its depletion leaves unaltered sensorimotor deficits or histopathology. Scientific Reports, 2021, 11, 9616.	3.3	12
4	Circulating and Synovial Pentraxin-3 (PTX3) Expression Levels Correlate With Rheumatoid Arthritis Severity and Tissue Infiltration Independently of Conventional Treatments Response. Frontiers in Immunology, 2021, 12, 686795.	4.8	11
5	Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity. , 2021, 9, e002408.		43
6	Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clinical Immunology, 2020, 220, 108598.	3.2	191
7	PLGA Based Nanoparticles for the Monocyte-Mediated Anti-Tumor Drug Delivery System. Journal of Biomedical Nanotechnology, 2020, 16, 212-223.	1.1	26
8	Tumor-Associated Myeloid Cells in Cancer Progression. , 2020, , 29-46.		1
9	The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell–mediated resistance to metastasis. Nature Immunology, 2019, 20, 1012-1022.	14.5	75
10	Pentraxin 3 deficiency protects from the metabolic inflammation associated to diet-induced obesity. Cardiovascular Research, 2019, 115, 1861-1872.	3.8	36
11	ACKR2 in hematopoietic precursors as a checkpoint of neutrophil release and anti-metastatic activity. Nature Communications, 2018, 9, 676.	12.8	68
12	The Long Pentraxin 3 Plays a Role in Bone Turnover and Repair. Frontiers in Immunology, 2018, 9, 417.	4.8	41
13	Molecular Signatures of Immunity and Immunogenicity in Infection and Vaccination. Frontiers in Immunology, 2017, 8, 1563.	4.8	18
14	Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1182-1190.	3.8	32
15	Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation. Oncotarget, 2016, 7, 82123-82138.	1.8	6
16	An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. Journal of Experimental Medicine, 2015, 212, 905-925.	8.5	128
17	Recognition of Neisseria meningitidis by the Long Pentraxin PTX3 and Its Role as an Endogenous Adjuvant. PLoS ONE, 2015, 10, e0120807.	2.5	29
18	Alveolar pentraxin 3 as an early marker of microbiologically confirmed pneumonia: a threshold-finding prospective observational study. Critical Care, 2014, 18, 562.	5.8	44

#	Article	IF	CITATIONS
19	Endothelial Cell–Derived Chemerin Promotes Dendritic Cell Transmigration. Journal of Immunology, 2014, 192, 2366-2373.	0.8	51
20	Long Pentraxin 3/Tumor Necrosis Factor-Stimulated Gene-6 Interaction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 696-703.	2.4	69
21	Failure to detect production of IL-10 by activated human neutrophils. Nature Immunology, 2011, 12, 1017-1018.	14.5	70
22	Pathogen Recognition by the Long Pentraxin PTX3. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-15.	3.0	67
23	Regulation of leukocyte recruitment by the long pentraxin PTX3. Nature Immunology, 2010, 11, 328-334.	14.5	396
24	The pattern of response to anti–interleukinâ€1 treatment distinguishes two subsets of patients with systemicâ€onset juvenile idiopathic arthritis. Arthritis and Rheumatism, 2008, 58, 1505-1515.	6.7	346
25	Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. Journal of Leukocyte Biology, 2008, 84, 1540-1548.	3.3	67
26	Cell-specific Regulation of PTX3 by Glucocorticoid Hormones in Hematopoietic and Nonhematopoietic Cells. Journal of Biological Chemistry, 2008, 283, 29983-29992.	3.4	78
27	Impact of the anti-inflammatory agent bindarit on the chemokinome: selective inhibition of the monocyte chemotactic proteins. European Cytokine Network, 2008, 19, 119-22.	2.0	46
28	Complement Dependent Amplification of the Innate Response to a Cognate Microbial Ligand by the Long Pentraxin PTX3. Journal of Immunology, 2007, 179, 6311-6317.	0.8	53
29	Increased Susceptibility to Colitis-Associated Cancer of Mice Lacking <i>TIR8</i> , an Inhibitory Member of the Interleukin-1 Receptor Family. Cancer Research, 2007, 67, 6017-6021.	0.9	115
30	Regulation of the microsomal prostaglandin E synthase-1 in polarized mononuclear phagocytes and its constitutive expression in neutrophils. Journal of Leukocyte Biology, 2007, 82, 320-326.	3.3	43
31	The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood, 2007, 109, 3625-3632.	1.4	336
32	A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective) Tj ETQq0) 0 0 rgBT 1.4	/Overlock 10
33	Generation and characterization of a mouse lymphatic endothelial cell line. Cell and Tissue Research, 2006, 325, 91-100.	2.9	56
34	Differential regulation of chemokine production by Fc receptor engagement in human monocytes: association of CCL1 with a distinct form of M2 monocyte activation (M2b, Type 2). Journal of Leukocyte Biology, 2006, 80, 342-349.	3.3	131
35	Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. Journal of Experimental Medicine, 2005, 201, 509-515.	8.5	248
36	Transcriptional Profiling Reveals Complex Regulation of the Monocyte IL-1Î ² System by IL-13. Journal of	0.8	132

#	Article	IF	CITATIONS
37	Complexity and Complementarity of Outer Membrane Protein A Recognition by Cellular and Humoral Innate Immunity Receptors. Immunity, 2005, 22, 551-560.	14.3	271
38	Differential Recognition and Scavenging of Native and Truncated Macrophage-Derived Chemokine (Macrophage-Derived Chemokine/CC Chemokine Ligand 22) by the D6 Decoy Receptor. Journal of Immunology, 2004, 172, 4972-4976.	0.8	132
39	Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3522-3526.	7.1	236
40	Defective dendritic cell migration and activation of adaptive immunity in PI3KÎ ³ -deficient mice. EMBO Journal, 2004, 23, 3505-3515.	7.8	146
41	IL-8 induces a specific transcriptional profile in human neutrophils: synergism with LPS for IL-1 production. European Journal of Immunology, 2004, 34, 2286-2292.	2.9	30
42	Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia, 2003, 17, 52-59.	7.2	142
43	Activation of signal transducer and activator of transcription 3 in rat liver after heat shock and reperfusion stress. International Journal of Biochemistry and Cell Biology, 2003, 35, 316-323.	2.8	7
44	Cutting Edge: Scavenging of Inflammatory CC Chemokines by the Promiscuous Putatively Silent Chemokine Receptor D6. Journal of Immunology, 2003, 170, 2279-2282.	0.8	181
45	Cross-Linking of the Mannose Receptor on Monocyte-Derived Dendritic Cells Activates an Anti-Inflammatory Immunosuppressive Program. Journal of Immunology, 2003, 171, 4552-4560.	0.8	334
46	Analysis of the Gene Expression Profile Activated by the CC Chemokine Ligand 5/RANTES and by Lipopolysaccharide in Human Monocytes. Journal of Immunology, 2002, 168, 3557-3562.	0.8	164
47	Stimulation of toll-like receptor 4 expression in human mononuclear phagocytes by interferon-γ: a molecular basis for priming and synergism with bacterial lipopolysaccharide. Blood, 2002, 99, 3427-3431.	1.4	255
48	Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. Journal of Clinical Investigation, 2001, 107, 1173-1181.	8.2	275
49	Inhibition of Monocyte Chemotactic Protein-1 Synthesis by Statins. Laboratory Investigation, 2000, 80, 1095-1100.	3.7	282
50	Differential effect of benzydamine on pro- versus anti-inflammatory cytokine production: lack of inhibition of interleukin-10 and interleukin-1 receptor antagonist. International Journal of Clinical and Laboratory Research, 2000, 30, 17-19.	1.0	19
51	Redox regulation of chemokine receptor expression. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 2761-2766.	7.1	110
52	Vitamin D3 Affects Differentiation, Maturation, and Function of Human Monocyte-Derived Dendritic Cells. Journal of Immunology, 2000, 164, 4443-4451.	0.8	572
53	Characterization of type II intracellular IL-1 receptor antagonist (IL-1ra3): a depot IL-1ra. European Journal of Immunology, 1999, 29, 781-788.	2.9	30
54	The sympathetic nervous system tonically inhibits peripheral interleukin-1β and interleukin-6 induction by central lipopolysaccharide. Neuroscience, 1998, 83, 1245-1250.	2.3	46

#	Article	IF	CITATIONS
55	Role of Metalloproteases in the Release of the IL-1 type II Decoy Receptor. Journal of Biological Chemistry, 1997, 272, 31764-31769.	3.4	108
56	Carrageenan-induced acute inflammation in the mouse air pouch synovial model. Role of tumour necrosis factor. Mediators of Inflammation, 1997, 6, 32-38.	3.0	70
57	Centrally Mediated Inhibition of Local Inflammation by Ciliary Neurotrophic Factor. NeuroImmunoModulation, 1997, 4, 271-276.	1.8	15
58	DIFFERENTIAL EFFECTS OF IL-6 ON SYSTEMIC AND CENTRAL PRODUCTION OF TNF: A STUDY WITH IL-6-DEFICIENT MICE. Cytokine, 1997, 9, 300-306.	3.2	48
59	Role of IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte Recruitment. Immunity, 1997, 6, 315-325.	14.3	1,022
60	Benzydamine inhibits the release of tumor necrosis factor-α and monocyte chemotactic protein-1 byCandida albicans-stimulated human peripheral blood cells. International Journal of Clinical and Laboratory Research, 1997, 27, 118-122.	1.0	42
61	A glucocorticoid receptor-independent mechanism for neurosteroid inhibition of tumor necrosis factor production. European Journal of Pharmacology, 1996, 299, 179-186.	3.5	34
62	INHIBITION OF INFLAMMATORY CYTOKINE PRODUCTION AND PROTECTION AGAINST ENDOTOXIN TOXICITY BY BENZIDAMINE. Cytokine, 1996, 8, 710-716.	3.2	46
63	Monocyte function in a severe combined immunodeficient patient with a donor splice site mutation in the Jak3 gene. Blood, 1996, 88, 817-823.	1.4	43
64	In vivo exposure to NO2 reduces TNF and IL-6 production by endotoxin-stimulated alveolar macrophages. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1996, 271, L132-L138.	2.9	6
65	Overexpression of interleukin-6 in the central nervous system of transgenic mice increases central but not systemic proinflammatory cytokine production. Brain Research, 1996, 740, 239-244.	2.2	42
66	Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion. Arthritis and Rheumatism, 1996, 39, 758-766.	6.7	132
67	Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface "receptor" with anti-interleukin-1 function Journal of Experimental Medicine, 1996, 183, 1841-1850.	8.5	95
68	Reactive oxygen intermediates cause rapid release of the interleukin-1 decoy receptor from human myelomonocytic cells. Blood, 1996, 87, 1682-1686.	1.4	13
69	Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1. Blood, 1996, 87, 1851-1854.	1.4	0
70	Interleukin-10 Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor and Interleukin-1β Production in the Brain without Affecting the Activation of the Hypothalamus-Pituitary-Adrenal Axis. NeuroImmunoModulation, 1995, 2, 149-154.	1.8	53
71	Effects of granulocyteâ€monocyte colonyâ€stimulating factor (GMâ€CSF) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancerâ€associated macrophages. International Journal of Cancer, 1995, 60, 300-307.	5.1	36
72	Second International Cytokine Conference, Banff, Alberta October 1–5, 1994. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1995, 2, 66-68.	3.0	0

#	Article	IF	CITATIONS
73	Cloning and characterization of a new isoform of the interleukin 1 receptor antagonist Journal of Experimental Medicine, 1995, 182, 623-628.	8.5	112
74	Ciliary Neurotrophic Factor (CNTF) Induces Serum Amyloid A, Hypoglycaemia and Anorexia, and Potentiates IL-1 Induced Corticosterone and IL-6 Production in Mice. Cytokine, 1995, 7, 150-156.	3.2	40
75	Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin. Vaccine Journal, 1995, 2, 549-553.	2.6	112
76	Regulation of endothelial and mesothelial cell function by interleukin- 13: selective induction of vascular cell adhesion molecule-1 and amplification of interleukin-6 production. Blood, 1994, 84, 1913-1921.	1.4	104
77	Interleukin-13 induces the production of interleukin-1 receptor antagonist (IL-1ra) and the expression of the mRNA for the intracellular (keratinocyte) form of IL-1ra in human myelomonocytic cells. Blood, 1994, 83, 1738-1743.	1.4	88
78	Induction by transforming growth factor-β1 of the interleukin-1 receptor antagonist and of its intracellular form in human polymorphonuclear cells. European Journal of Immunology, 1994, 24, 3194-3198.	2.9	28
79	Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells Journal of Cell Biology, 1994, 127, 537-546.	5.2	490
80	Cytokines in Acute Myocardial Infarction. Journal of Cardiovascular Pharmacology, 1994, 23, 1-6.	1.9	90
81	Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors Proceedings of the National Academy of Sciences of the United States of America, 1994. 91. 7291-7295.	7.1	154
82	Divergent effects of interleukin-10 on cytokine production by mononuclear phagocytes and endothelial cells. European Journal of Immunology, 1993, 23, 2692-2695.	2.9	73
83	Mast cells do not contribute to the rapid appearance of the TNF in the serum of LPS-treated mice: A study with mast cell-deficient mice. International Journal of Immunopharmacology, 1993, 15, 551-555.	1.1	6
84	Inhibitors of Cytochrome P450 Suppress Tumor Necrosis Factor Production. Cellular Immunology, 1993, 150, 417-424.	3.0	16
85	Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science, 1993, 261, 472-475.	12.6	935
86	Differential Expression of the Common β and Specific α Chains of the Receptors for GM-CSF, IL-3, and IL-5 in Endothelial Cells. Experimental Cell Research, 1993, 206, 311-317.	2.6	63
87	Molecular mapping and detoxification of the lipid A binding site by synthetic peptides. Science, 1993, 259, 361-365.	12.6	148
88	Role of acute-phase proteins in interleukin-1-induced nonspecific resistance to bacterial infections in mice. Antimicrobial Agents and Chemotherapy, 1993, 37, 2527-2533.	3.2	34
89	Type II interleukin-1 receptor is not expressed in cultured endothelial cells and is not involved in endothelial cell activation. Blood, 1993, 81, 1347-1351.	1.4	31
90	Modulation of systemic interleukin-6 induction by central interleukin-1. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1993, 265, R739-R742.	1.8	22

#	Article	IF	CITATIONS
91	Evidence for a different sensitivity to various central effects of interleukin-1 β in mice. Brain Research Bulletin, 1992, 28, 161-165.	3.0	25
92	Inhibitory effect of recombinant intracellular interleukin 1 receptor antagonist on endothelial cell activation. Cytokine, 1992, 4, 44-47.	3.2	33
93	Interleukin 4 amplifies monocyte chemotactic protein and interleukin 6 production by endothelial cells. Cytokine, 1992, 4, 24-28.	3.2	56
94	The unique interaction with immunity of FCE 24517, an antitumor drug with a novel mode of action. International Journal of Immunopharmacology, 1992, 14, 239-251.	1.1	5
95	Diffferential sensitivity of in vivo TNF and IL-6 production to modulation by anti-inflammatory drugs in mice. International Journal of Immunopharmacology, 1992, 14, 1045-1050.	1.1	51
96	N-Acetylcysteine and glutathione as inhibitors of tumor necrosis factor production. Cellular Immunology, 1992, 140, 390-399.	3.0	233
97	Interleukin 6 activity in infants and children with bacterial meningitis. Pediatric Infectious Disease Journal, 1991, 10, 117-121.	2.0	64
98	Mouse macrophage clones immortalized by retroviruses are functionally heterogeneous Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 7543-7547.	7.1	38
99	Involvement of leukocyte (β2) integrins (CD18/CD11) in human monocyte tumoricidal activity. International Journal of Cancer, 1991, 49, 267-273.	5.1	25
100	Chemoattractant(s) in Culture Supernatants of HTLV-I-Infected T-Cell Lines. AIDS Research and Human Retroviruses, 1991, 7, 571-577.	1.1	8
101	3-methylcholanthrene induces differential inhibition of humoral and cell mediated immune responses in mice of different ages. Toxicology, 1990, 60, 263-273.	4.2	4
102	In vivo effects of cyclosporin A on murine B-cells responding to type III pneumococcal polysaccharide. International Journal of Immunopharmacology, 1990, 12, 359-364.	1.1	0
103	Interleukin-6 gene expression and production induced in human monocytes by membrane proteoglycans from Klebsiella pneumoniae. International Journal of Immunopharmacology, 1990, 12, 397-402.	1.1	14
104	Intracerebroventricular injection of interleukin 1 induces high circulating levels of interleukin 6 Journal of Experimental Medicine, 1990, 171, 1773-1778.	8.5	154
105	Differential effect of central and peripheral IL-1Î ² administration on serum corticosterone and IL-6 levels and food and hater intake. Pharmacological Research, 1990, 22, 311.	7.1	0
106	Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia. Blood, 1989, 73, 1279-1284.	1.4	115
107	Monokine production by microglial cell clones. European Journal of Immunology, 1989, 19, 1443-1448.	2.9	355
108	IL-1 and IL-6 release by tumor-associated macrophages from human ovarian carcinoma. International Journal of Cancer, 1989, 44, 795-801.	5.1	91

#	Article	IF	CITATIONS
109	Effect of anticancer drugs on in vitro lak cell generation. International Journal of Immunopharmacology, 1988, 10, 23.	1.1	0
110	Enhancement of humoral antibody production by cyclosporin A. International Journal of Immunopharmacology, 1988, 10, 70.	1.1	0
111	In vitro activation of murine macrophage functions by the bacterial extract OM89. International Journal of Immunopharmacology, 1988, 10, 153.	1.1	0
112	Effect of thymostimulin in models of cell-mediated and humoral autoreactivity and on T-dependent suppression. International Journal of Immunopharmacology, 1987, 9, 937-945.	1.1	0
113	A preliminary analysis of the effects of elliptinium on immune reactivities in mice. European Journal of Cancer & Clinical Oncology, 1986, 22, 637-645.	0.7	6
114	Effect of inducers of P-450 cytochrome isoenzymes on TCDD immunosuppressive activity. Chemosphere, 1986, 15, 1707-1714.	8.2	3
115	Simultaneous administration of TCDD and TDCF at different ratios induces different effects. Chemosphere, 1985, 14, 957-961.	8.2	1
116	Immunosuppressive effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin in strains of mice with different susceptibility to induction of aryl hydrocarbon hydroxylase. Toxicology and Applied Pharmacology, 1983, 68, 434-441.	2.8	137
117	Toxicological evaluation of urban waste incinerator emissions. Chemosphere, 1983, 12, 559-564.	8.2	18
118	Effect of acute exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin on humoral antibody production in mice. Chemico-Biological Interactions, 1980, 30, 337-342.	4.0	68
119	Macrophage-mediated cytostatic activity on tumour cells after treatment with Triton WR 1339. European Journal of Cancer, 1978, 14, 229-235.	0.9	1
120	Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment. Oncotarget, 0, 7, 41662-41676.	1.8	66